Shri K V Balasubramaniam, Managing Director, Indian Immunologicals Ltd holds a graduate degree in Mechanical Engineering from the Madras University (1979) and a masters degree in management from the Indian Institute of Management, Ahmedabad ( 1981). He has over 27 years experience in managing industrial enterprises, with nearly 22 years in the pharmaceutical industry. He joined Indian Immunologicals in 1996 as Chief Executive and has been instrumental in reviving the fledgling unit of the National Dairy Development Board and making it a professionally managed, performance driven and result oriented vaccine player. He was inducted into the Board as Managing Director in 1999. Indian Immunologicals is today the No 1 animal vaccine player , the 3rd largest animal health company, 4th largest vaccine company- both human and animal vaccines, and the 8th largest biotech company in India. Shri Balasubramaniam has been a speaker on both the subject of management and on bio-technology in various national and international forums. He has been a regular speaker on topics concerning vaccine manufacture, vaccine development and access in developing countries and emerging markets.

Dr Emma Ball is Program Director of Influenza, CSL Limited in Melbourne, Australia. She oversees the management of R&D projects within CSL’s Influenza Vaccine R&D portfolio. Emma joined CSL in 2006 as a Senior Project Manager within the Influenza R&D group. Prior to joining CSL, Emma worked in project management in small biotech. She trained initially as a molecular biologist and gained her PhD in 1999 from the University of Melbourne, followed by Postdoctoral studies in oncology & endocrinology at Monash University, Melbourne. Emma also holds an MBA from RMIT University, Melbourne.

As Director of Regulatory Affairs for CSL Limited, Jillian is responsible for the overall global regulatory activities for all development and marketed products within the company's portfolio. Jillian has 25 years experience in the pharmaceutical industry, initially as a research scientist working on a range of vaccine and clinical research projects, before being recruited to a role in Regulatory Affairs in 1993. In her current role she has successfully combined her research and product development skills with her regulatory skills, to provide strategic leadership to a team responsible for the regulatory science, nonclinical safety programs and strategic oversight of biological product development through all phases from preclinical to registration. Jillian spearheaded the registration of CSL's thiomersal free influenza vaccine in 27 countries including countries within the Asia Pacific Region and the EU, and the USA; this includes the first product to be successfully registered in the USA manufactured by CSL Limited in Australia.

Alain Bouckenooghe obtained his MD at the Catholic University of Leuven, Belgium, before leaving on assignment with the Ministry of Health in Zambia, where he worked as General and District Medical Officer for several years. Subsequently, Dr Bouckenooghe moved to the US and completed his residency at the University of Texas, Houston. He obtained his MPH degree at the UT School of Public Health and completed a fellowship in Infectious Diseases at Baylor College of Medicine. Alain held several academic positions during this time, the most recent being that of Assistant Professor in the Department of Medicine at Baylor College. He joined sanofi pasteur in December 2006 in Swiftwater, PA, USA, coming from GlaxoSmithKline Biologicals, where he led the rotavirus vaccine clinical development program. Prior to his appointment at GSK, he held the position of Director, Regulatory Affairs with MSD Europe. He is currently located in Singapore as Associate VP and Head of Clinical R&D for sanofi pasteur in Asia.

Rodney started his career in vaccines at CSL where he worked in Influenza vaccine development but also spent some time in Quality Control of viral vaccines. He implemented many changes to the Influenza vaccine manufacturing process which included process validation and submission of documentation to the National Regulatory Authority (TGA) to approve the changes. After CSL he joined Sartorius Australia in the position of technical manager where he assisted vaccine and pharmaceutical companies in Australia and Asia to develop downstream processes and optimize filtration systems. He also provided critical support in the validation of numerous filtration systems with key customers. He joined the International Vaccine Institute (IVI) in Seoul Korea in June 2003 and is currently head of vaccine development. He led the investigation into the suitability of the Vietnamese oral cholera vaccine for technology transfer and discovered that it did not comply with the WHO requirements. This led to a reformulation of the vaccine resulting in a vaccine that has an improved safety profile, is significantly more immunogenic and is now compliant with the WHO requirements. The reformulated vaccine is now in phase III clinical trials and technology transfer to a developing country manufacturer has been completed. He also leads a laboratory team at IVI which focuses on product development with a strong emphasis on compatibility with large scale manufacture under GMP conditions. The team has optimized yields of Vi capsular polysaccharide produced by Salmonella typhi and improved the purification process. The Vi is the main component of parenteral typhoid fever vaccines. A Vi-DT (Diphtheria Toxoid) conjugate vaccine has also been developed in the laboratories and the process of technology transfer of the Vi conjugate is now underway.

Dr Stephen Cook is Vice President and Head of Worldwide Vaccine Registration Management for GlaxoSmithKline Biologicals based in Belgium. In this role, he has responsibility for the definition and implementation of regulatory strategy to ensure that GlaxoSmithKline Beecham Biologicals assets are registered globally. Prior to this, and from 2003 to end 2007, he was Vice President for Regulatory Affairs in the Asia Pacific area (based in Singapore) for GlaxoSmithKline with overall responsibility for all GSK regulatory activities in that region of the world. Dr Cook joined the pharmaceutical industry in 1986 working in the area of Active Pharmaceutical Ingredient (API) manufacture and Quality Assurance before moving into Regulatory Affairs in 1993. He is experienced in the registration of medicinal products in Europe and has extensive first hand experience of regulatory affairs across the International region (ie, Asia, Africa, Central Eastern Europe, Latin America and the Middle East) for both pharmaceutical and biological products. Dr Cook is a graduate of the University of Strathclyde (Glasgow, UK) where he completed a BSc (Hons.) in Applied Chemistry and then an MSc followed by a PhD in Analytical Chemistry. He is a Member of the Royal Society of Chemistry and a Chartered Chemist. He was granted the designation of Chartered Scientist (CSci) in 2004 by the (UK) Science Council. He has been a Member of The Organisation of Professionals in Regulatory Affairs [previously the British Institute of Regulatory Affairs] since 1994. He has participated in various APEC LSIF activities, delivered training and lectures on ICH country regulatory requirements and presented at many conferences on subjects as diverse as the drug development process, quality control, electronic document management, BSE/TSE, batch release requirements for vaccines and the role of regulatory affairs in the pharmaceutical industry.

Fiona Garín is currently the Director for Strategic Marketing for BD Medical Surgical Systems in Europe. Over the past 2 years she was responsible for leading and coordinating the effective development and implementation of BD’s strategy for influenza preparedness in Europe, for establishing close cooperation between BD and vaccine manufacturers on vaccine delivery solutions related to a pandemic preparation situation, and for leading advocacy efforts at NGO, multi and bilateral, and MOH levels on Seasonal and Pandemic Influenza solutions. Before that Fiona was BD´s worldwide director for strategic marketing for 7 years, and was responsible for directing overall strategic and marketing efforts to meet developing country safe immunization needs. Prior to joining BD, she was a Health Specialist in the World Bank, managing Health Reform Projects under preparation and implementation in Central America, and a consultant for several years in Price Waterhouse´s Strategic Consulting Group. Fiona has a Master of Science in International Affairs from Georgetown University School of Foreign Service, and a Graduate Certificate in International Health and Development from George Washington University, both in Washington, DC, USA. Her undergraduate degree was in European Business Studies and she has a BA (Hons) from Hull University in the UK, and the “Centro Europeo de Gestión de Empresas” in Spain.

Jaap Goudsmit received his MD degree from the Faculty of Medicine of the University of Amsterdam in 1978 and his PhD degree from the same university in 1982. In 1978 he was awarded a Fogarty fellowship and in 1982 a Fogarty visiting scientist award to postdoctoral research at the National Institutes of Health in Bethesda, Maryland USA. In 1983 Jaap Goudsmit was board certified in the Netherlands as a Medical Microbiologist. From 1996 till 2002 Jaap Goudsmit has been head of the Department of Human Retrovirology at the Academic Medical Center (AMC) of the University of Amsterdam (UvA). From 1989 till 2002 Jaap Goudsmit was affiliated to the AMC as full Professor of virology. From 1999 till 2002 Jaap Goudsmit was chairman of the AMC Research Institute for Infectious Diseases and chairman of the AMC Institute for Science Education. Since 1984 Jaap Goudsmit is one of the principal investigators of the Amsterdam Cohort Studies of homosexual men and IV drug users, focusing on the natural history and the pathogenesis of AIDS. Jaap Goudsmit is the founder (1993) of the first biotech company concentrating completely on predictive medicine: PrimaGen. He has been its chief scientific officer until March 2002, thereafter he holded the position of chairman of the Scientific Advisory Board of PrimaGen until June 2004. From 1994-2002 Jaap Goudsmit chaired the Scientific Advisory Committee of the International AIDS Vaccine Initiative (IAVI), the premier non-governmental driving force for a global HIV vaccine. From 2000 till 2004 he has been a member of the board. From 1993-1996 Jaap Goudsmit was visiting professor at the Aaron Diamond AIDS Research Center of New York University, USA. From 1993 till 2002 Jaap Goudsmit has been project leader and (co)chair of Eurovac, the EU AIDS vaccine effort to bring promising vaccine concepts to phase I human testing. In the period 1981-2001 Jaap Goudsmit published over 450 scientific articles in peer-reviewed journals and was considered by Science in 1993 the most influential AIDS scientist of Europe. According to a survey in 2001 of the Institute of Scientific Information Jaap Goudsmit is one of the world’s most cited scientific authors, a group comprising of less than one half of one percent of all published researchers. In 1997 he published a book with Oxford University Press, entitled "Viral Sex, the Nature of AIDS" of which the New York Times Book Review said: "It is full of astonishing and interesting facts not only about viruses but about the humans studying them" and the Lancet: "A well-written and provocative treatise about the origins of HIV and about the evolution of this most perplexing virus". In July 2004 his book "Viral Fitness, the next SARS and West Nile in the making" has been released. In 2002 Jaap Goudsmit has been affiliated to AMC through his appointment of Professor of poverty-related communicable diseases. In this capacity he will continue to chair the board of the in 2001 initiated Center of Poverty-related Communicable Diseases (CPCD), a joint initiative of the AMC, the Royal Tropical Institute (KIT), the Royal Netherlands Tuberculosis Association (KNCV), and PharmAccess International (PAI). As per March 2002 Jaap Goudsmit is affiliated with Crucell, a leading biotechnology company in Leiden. He started as Senior Vice President Vaccine Research. In July 2002 he accepted the position of Chief Medical Officer and became a member of the Executive Committee as Executive Vice President Vaccine Research and Development. Since September 2002 he holds the position of Chief Scientific Officer and Head Research and Development. In January 2004 he became a member of Crucell's Management Board. In August 2003 Jaap Goudsmit accepted his appointment as chairman of the board of the AIDS Foundation East-West, an NGO focused on AIDS prevention in the countries of the former Soviet Union. In December 2003 Jaap Goudsmit has been elected as member of the HIV Vaccine Enterprise Product Development Working Group of the Gates Foundation. Since March 2006 Jaap Goudsmit is affiliated with Pevion as member of the Supervisory Board. In the same month he entered the Board of Vaxin Inc. Also in 2006 Jaap Goudsmit accepted his appointment as member of the Scientific Advisory Board of the Eurovacc Foundation.

Dr. Yoshinori Hayakawa completed his PhD at the department of Nuclear Engineering, Tokyo Institute of Technology in 1975. In 1976, he initiated to researched as Lecturer at Teikyo University School of Medicine. He engaged in researches on Boron-neutron capture therapy of brain tumor and Hyperthermia by ultrasound. In 1980, he initiated to research in Institute of Basic Medical Sciences in Tsukuba University as Associate Professor.. He engaged in proton cancer therapy and ultrasound tissue characterization. In 1999, he initiated to research in Toin University of Yokohama as associate professor. He is currently full professor in Department of Clinical Engineering. He is currently engaged in prevention of infectious disease ,i.e., prevention of highly pathological influenza H5N1 pandemic and prevention of spread of HIV, tuberculosis and malaria by eradication of poverty in developing countries. For later purposes he has invented Abacus Numerals for Numeracy and Universal Alphabet for Literacy for shortening necessary period for efficient basic education. His another current researches are improvements of breast cancer diagnosis and of cancer therapy by Hyperthermia.

Ms. Parminder Kaur is a Regulatory Affairs professional with Global expertise. Ms. Kaur gained post-graduate degree in Biotechnology from GGU, India prior to joining industry in 1998.She has been working in the field of regulatory affairs for the last 11 years and gained expertise for major markets in the world during her tenure. Ms. Kaur has hands-on experiences in pharmaceutical and biotechnology industries and interaction with major Regulatory Authorities esp. EU Authorities. She has provided strategic input for regulatory matters regarding new product development aimed for global launch, development of Biosimilars for EU market as well as registration of old vaccines in the EU. Ms. Kaur is highly involved with advising and preparation of Clinical Trial and Marketing Authorisations Applications, Variations Applications, Drug/Device/Plasma/Vaccine-Antigen Master Files, Orphan Drug Designations, Paediatric Investigational Plans (PIP) and Scientific Advice Briefing Books including writing, and editing various technical documents as per CTD format. She has also been highly involved in the Pharmacovigilance set-up at various companies and has been involved to a great extent with writing and managing pharmacovigilance plans, risk minimization plans and SAE reporting. She has also played a major role in setting the QA systems in compliance with the European legislation at various companies throughout her tenure. She has assisted various companies during Inspections and Audits conducted by Regulatory Authorities. In March 2007, Ms. Kaur had been selected by the European Federation of Pharmaceutical Industries and Association (EFPIA) for her global expertise and also had an honour to be the Scientific Representative from India for the year 200-2001, duly sponsored by UNESCO. Ms. Parminder Kaur is currently having her own consulting firm by the name of RegPak BioPharma Consulting and is based in Amsterdam, The Netherlands.

Dr. Wu Ke is Vice President of Shanghai Zerun Biotechnology Co., Ltd., a biotech company focused in R&D, manufacture and marketing for human vaccines as well as other biologicals like monoclonal antibodies. The company formerly named Shanghai Wison Bioengineering Co., Ltd., founded in Zhangjiang National Hitech Park in 2003. He is in charge of management for R&D, QA/QC, Production, Engineering, Regulatory Affairs, also experienced in business development, technology transfer, product introduction, facility evaluations, etc. He has 21 years of experience in industry and had successfully developed 6 products being approved by SFDA and marketed in China. Prior to join Wison in 2004, Dr. Wu Ke was Director of R&D in Wuhan Institute of Biological Products (WIBP) of China National Biotec Group (CNBG), the biggest biotech company in Asia. He was department manager for blood products, department manager for cell biology and project manager for tumor research in WIBP. He hold a BA degree in biochemistry and a PhD in Immunology, also had a certificate of senior management from China Europe International Business School (CEIBS).

Peter H. Khoury, Ph.D., MBA is the Global Vice President for Baxter Vaccines. He obtained his docterate in Microbiology from Syracuse University in 1991, studying the effects of heat shock proteins on the resistance of bacterial spores. Dr. Khoury also holds a MBA from Cornell University's Johnson Graduate School of Management in marketing and general management. Peter has worked during the past fifteen years in various sales and marketing positions of increasing responsibility with Merck Vaccine Division, and Baxter Vaccines. His responsibilities have included Business Development, Promotion Management, Physician and Institutional Sales, Product Management, Database and Direct Marketing, International Marketing, and Global Marketing Strategic Development. He has been a key member of the launch teams for two vaccine products, Varivax and Comvax Dr. Khoury’s current responsibilities in his position as Vice President, Global Marketing for Baxter International (BioScience Division) includes both vaccines sales and marketing for Latin America, North America, Asia, and the Pacific Region, government contracting, and business development.

Christoph S. Klade is a biochemist and immunologist by training. He obtained his PhD from the University of Vienna and obtained further training in immunology at the Universities of Berkeley and Stanford, California. After university Dr. Klade spent over fourteen years in industrial research and development. These years included setting up of technology platforms for identification of both B- and T-cell antigens, discovery research, assay development and validation and close involvement in clinical research. At Intercell AG he set up the Department of Clinical Immunology responsible for all immunological monitoring of Intercell´s vaccine trials including T-cell and serology assays. Recently, data from this department was the basis for successful pivotal phase III trials in the development of a novel prophylactic vaccine against Japanese encephalitis virus (Tauber&Klade 2007, The Lancet, 370:1847-53). Currently Dr. Klade serves as VP Technology & Clinical Development / Clinical Immunology at Intercell AG, overlooking functions such as Clinical Development, Clinical Immunology, Process Development and Analytical and Formulation Development.

Por Lai is the Founder of Dephoron Group which explores investment opportunities in life sciences. Between 2000 and 2007, Lai managed President Life Sciences, a prominent Taiwanese corporate fund. Between 1981 and 2000, he held various management positions with US biotech companies including Sequemat, Amgen, Centocor, SBH Sciences, and Protein Institute where he developed biotech instruments, and protein drugs such as rhEPO, rhG-CSF, antibodies and other biologics for human uses, and managed cytokine businesses. In 1992, Lai also co-founded the Kirin Pharmaceuticals Co., Ltd. with Kirin Brewery of Japan and developed its biopharmaceutical markets in the Greater China. Lai has published 40+ scientific papers, patented key biotech patents, and has been an adjunct faculty member with University of Kentucky and Kaohsiung Medical University. He has served as an advisor to various offices of the Taiwan government on biotech programs, and served on the boards of directors of 15+ companies and organizations. He received a pharmacy degree from Kaohsiung Medical College and Ph.D. in Chemistry from Massachusetts College of Pharmacy.

Florence is a Professional Interim Manager to biotechs and pharmaceutical companies, who needs an independent mind and action bias executor, to bridge their internal talent gap as they strives for commercial success in Asia. She is also an Investment Director with ATP Capital, a Singapore based biotech focused venture capital. Florence joined the venture capital industry after eighteen years of senior leadership position with top pharmaceuticals multinationals. Florence set up the full fledged Sanofi-Synthelabo operation in Singapore after separation of management control from Malaysia in 2002. Thereafter she was responsible for the rapid integration of Sanofi-Synthelabo and Aventis Singapore driving organizational restructuring, operational efficiency, strategic development to strengthen market presence after the merger. Prior to sanofi-aventis, Florence spent ten years in various senior management positions in GSK Singapore and in GlaxoWellcome’s Head Office in the United Kingdom. Florence started her career in the finance industry then moved over to the pharmaceutical industry joining Roche Singapore as a Sales Executive before rapidly taking on responsibilities in sales and product management.

Ms Ma has been an advisor to TVM Capital since late 2004 and joined TVM Capital as Venture Partner for life sciences in 2007. She entered the life sciences industry in 2000 when she was a Senior Vice President at Vertex Management, where she co-led the Global Biotechnology Investment Division. Since 2003, she has been advising life sciences businesses wishing to expand or raise funds in Asia. Prior to 2000, she accumulated over 16 years of international investment, corporate finance and general management experience with Singapore Technologies, Banque Nationale de Paris, General Electric (USA), Morgan Grenfell, Booz, Allen & Hamilton and Price Waterhouse. Ms Ma holds a MSc in Biotechnology from the Johns Hopkins University, USA, a MBA from Manchester Business School, UK and a Bachelor of Accountancy from the National University of Singapore.

Jacques-François Martin has spent the essence of his career in the pharmaceutical, biological and life sciences industries. In 1991, Martin set up Parteurop S.A, a biotech consulting company based in Lyon, France. At Parteurop, Martin as Chairman and CEO, helps establish start-up companies by leveraging innovation from French and foreign institutions. From November 1997 to June 2003 he was a member of the Board of the International AIDS Vaccine Initiative (IAVI). From 2000 to January 2005, Martin held the position of President of The Vaccine Fund. He lead the Fund’s efforts to provide lifesaving vaccines and other immunization program support to low-income countries. In this capacity, he was also a member of the Board of GAVI (Global Alliance for Vaccines and Immunization).

Herve Mommeja-Marin received his MD from the University of Paris, France followed by specialty training in Internal Medicine and Infectious diseases. Dr. Mommeja-Marin moved to the U.S. in 2001 and worked in the drug development industry for Triangle Pharmaceuticals and then Gilead Sciences Inc., where he was responsible for coordination of medical affairs, regulatory functions, statistical analysis, data management, materials management, medical monitoring, publications, marketing, and vendor management. As the project leader for three hepatitis compounds he was responsible for the overall development from program design to NDA. His leadership involved implementation of worldwide phase I through IV studies in North America, Europe, and Asia-Pacific, filing of 2 INDs, numerous IMPDs, and successful NDA and EMEA filings for an HIV compound. Dr. Mommeja-Marin also served as lead presenter to advisory boards in Europe, NA, Australia, and New-Zealand and was responsible for set up, charter negotiation and internal contact for data monitoring committees. Dr. Mommeja-Marin also acted as a medical and scientific advisor for two HCV compounds in early clinical development. In parallel, Dr Mommeja-Marin has remained very active within the scientific community authoring 9 publications between 2001 and 2006 in major medical journals (Hepatology, Journal of Infectious Disease, Clinical Infectious Disease) focusing on natural history, surrogate markers and pathophysiology as well as public health pertaining to viral diseases. Dr Mommeja-Marin is a member of the European Association for the Study of the Liver, has presented to several international conferences (AASLD, EASL, DDW, ICAAC, international liver congress…), is a reviewer for medical journals and has advanced degrees in biostatistics and epidemiology. His areas of research interests include clinical pharmacology and microbiology, biostatistics, epidemiology, clinical investigation of new compounds for the treatment of infectious diseases, notably virus and parasites infections. At i3 research Dr. Mommeja-Marin acts as a consultant for sponsors in the development of new anti-infective therapies (HIV, vaccine, hepatitis B and C, HPV) and provides therapeutic leadership as well as strategic support to infectious diseases programs ran through one of the i3 companies.

Ms. Nayyar is PATH's country programme leader in India. Before joining PATH she worked with the International AIDS Vaccine Initiative (IAVI), where she was India country director and then vice president for country and regional programmes, working both in New Delhi and in New York at the organisation's headquarters. Ms. Nayyar holds a master's degree in population studies from Annamalai University, Tamil Nadu, India, and a bachelor’s degree with honours in English literature from St. Xavier's College, Bombay University. She began her career developing educational tools for kindergarten children and then joined the magazine parenting as assistant editor. Equipped with editorial and media relations experience, she was responsible for communications and advocacy activities for the South and East Asia Region at the Population Council from 1996 to 2002. During this period she planned and co-coordinated several advocacy and communications projects on reproductive and sexual health issues. She also conducted training programmes for researchers, government agencies and NGOs on reproductive and sexual health communication. She developed publications on emergency contraception, expanded and informed contraceptive choice, and reproductive tract infections (RTIs) and sexually transmitted infections (STIs) for the Population Council and for partner agencies such as the United Nations Population Fund. The government of India printed and distributed some of these publications on emergency contraception and RTIs and STIs to programme managers.

Dr.G.S.Reddy is the Chief General Manager of Indian Immunologicals Limited, a major human and veterinary vaccines manufacturer in India. He obtained basic degree in Veterinary medicine in 1981 from Andhra Pradesh Agricultural University, Hyderabad. He has 25 years of experience in industry, developing veterinary and human biologicals. Experience encompasses Quality, Research and Development, Manufacturing and Regulatory affairs. He is heading the team which is involved in manufacturing of various veterinary biologicals and human vaccines such as recombinant hepatitis B, Measles, DPT, TT, DT and DPTH vaccines. He worked on collaborative vaccine development projects with Georg August University, Gottingen, Germany and Centers for Disease Control and Prevention (CDC), Atlanta, USA. He is co-author of patent on DNA Rabies vaccine. He has published 40 scientific publications in various journals.

Joe Santangelo is the CEO and a founder of SingVax Pte. Ltd (incorporated in 2004), which is a privately held Singapore biotech company focusing on vaccines for human health. Prior to this he was one of the founding scientists of Microscience Ltd., where he served in R&D roles from its inception as a spin out from Imperial College of Science Technology and Medicine (UK) in 1997. His overall career in microbiology, infectious diseases and fermentation spans more than 25 years. Joe was born, educated and worked in the United States, before moving to South Africa, Germany, the United Kingdom and Singapore. He has worked in both academia and industry, and moved to the biotech sector 10 years ago.

Mr. Sheldon has been President and Chief Executive Officer of Medicago since August 2003. He has over twenty years of experience in the pharmaceutical industry. Before joining the company, Mr. Sheldon was Vice-President, Sales and Marketing, of Shire Biologics. He was responsible for international expansion with European, American and Asian private partnership agreements. He was also responsible for distribution, customer, maintenance and engineering at the Shire facility. He successfully negotiated the annual and pandemic contract with the federal and provincial governments. From 1998 to 2000, he was Senior Manager of Commercial Operations where successfully managed the approval of a bladder cancer therapeutic vaccine by the FDA. In 1997 and 1998, he was Marketing Manager for Merial Canada Inc. From 1992 to 1997, he was Director of Canadian Operations with Rhône Mérieux. From 1988 to 1992, he was National Sales Manager for SmithKline Beecham. Mr. Sheldon has a Bachelor Degree in Agricultural Sciences from Laval University, and a Bachelor of Science degree with Honours in Biological Sciences from the University of East Anglia, Norwich, England.

Derrick Sim is the Influenza Portfolio & Elderly Franchise Director at GlaxoSmithKline’s Asia Pacific regional operations and is responsible for marketing GSK’s seasonal, H5N1 pre-pandemic and pandemic influenza vaccines, antivirals and vaccines for the elderly population. In this capacity, he works closely with private and public sector stakeholders across Asia to meet their clinical, policy and business needs. Previously, he started up and headed GSK’s Vaccines Medical Affairs in Asia Pacific, supporting the launch of rotavirus and human papillomavirus vaccines. Derrick obtained his medical degree from Monash University, Australia and MBA from the Melbourne Business School, Australia. He gained his pediatric clinical experience there at the Royal Children's Hospital, where he was also involved in clinical research on hepatitis A and pediatric combination vaccines. He has received several awards and scholarships and serves on Melbourne Business School’s Alumni Advisory Council.

Alexander von Gabain obtained his Ph.D. in Genetics at the University of Heidelberg and held a post-doctorate position at the Stanford University. In the 1980s and 1990s he was a Professor at the University of Umeå and at the Karolinska Institute, Sweden as well as advisor to pharmaceutical and biotech companies. During 1992-1998 he was Chair of Microbiology at the University of Vienna at the Campus Vienna Biocenter, Austria. In 1998 he co-founded Intercell AG and led the company as CEO, until it was successful floated on the Vienna Stock Market in 2005. He is holding a professorship of Microbiology at the Max Perutz Laboratories, Vienna and a foreign adjunct professorship at the Karolinska Institute in Stockholm. He is member of several professional organizations and serves in the Supervisory Boards of biotech enterprises, including TVM Capital in Munich. Recently, he has been appointed into the founding Supervisory Board of the European Institute of Technology.

Mansour Yaich, PhD, Vaccine Development Director at PATH, is responsible for establishing and implementing the project's vaccine development agenda. Streamlining the process to move JE vaccine candidates through regulatory approval by health authorities, Dr.Yaich's responsibilities are wide-ranging from initiating clinical trial activities and establishing partnerships with vaccine manufacturers to negotiating contracts and selecting service companies. Coordinating these elements and overseeing their implementation is a delicate balance that draws upon Dr Yaich's experience in the pharmaceutical industry, where he tackled the complexities of vaccine development and clinical trials across four continents before joining PATH in October 2004. At Sanofi Pasteur, he served for eight years as Global Clinical Regulatory Officer and Project Team Leader for several new viral and bacterial vaccine candidates. Previously, he spent one year in the experimental virology unit at the Pasteur Institute, honing skills in molecular biology and cellular virology. Outside of the lab, Dr. Yaich worked during 4 years in a drug-testing unit specializing in pediatric infectious disease at the Clinical Pharmacology Unit of General Infant Robert Debre Hospital in Paris.

Ms. Lingjiang Yang, Manager, International Business and Cooperation, Chengdu Institute of Biological Products, and Regional Business Development Manager for Region II of CNBG Ms. Yang is Manager of International Business and Cooperation of CNBG Chengdu Institute and Regional Business Development Manager of CNBG. She has long experience in different project management and international business development. Now she is taking care about the cooperating project on live JE vaccine with PATH JE Project, responsible for establishing all the contacts and keeping good communication with outside, coordinating and auditing the internal project progress, managing the oversee registration and clinical studies. She is also responsible for developing new business in South Asia region for CNBG. She received a bachelor’s degree of arts from Sichuan University, China and now is studying on MBA.

Dr. Bing ZENG is Vice President of China National Biotec Group (CNBG) and responsible for international cooperation and business development of CNBG. Prior to joining CNBG in 2004, Dr. ZENG served in various multinational biotech and pharmaceutical companies including Boehringer Mannheim, Organon Teknika (a business unit of AKZO Nobel) and BIOMERIEUX for many years both in China and in Europe. Dr. Bing ZENG received his MBA degree from Nijenrode University (now named NIJENRODE BUSINESS UNIVERSITEIT), The Netherlands Business School in The Netherlands, and his Medical Degree from Beijing Medical University (now named The Medical School of Peking University) in Beijng, China. He practiced in China-Japan Friendship Hospital in Beijing as a Physician before he pursued his career in biotech Industry.